| Literature DB >> 29279095 |
Nele Boeckx1, Katleen Janssens2, Guy Van Camp3, Marika Rasschaert4, Konstantinos Papadimitriou5, Marc Peeters6, Ken Op de Beeck7.
Abstract
Colorectal cancer (CRC) is one of the most frequently diagnosed cancers worldwide. It has been reported that left- and right-sided CRC harbor varying disease characteristics, which leads to a difference in prognosis and response to therapy. Recently, there have been retrospective studies about tumor location in metastatic CRC (mCRC) and its potential to predict the effect of anti-vascular endothelial growth factor and anti-epidermal growth factor receptor (anti-EGFR) therapies. In this review, we provide a comprehensive overview of the latest trials studying the predictive value of primary tumor location in mCRC and discuss biomarkers that might be associated with the differences in treatment response. Although data need to be interpreted with caution due to the absence of randomized trials stratified based on tumor location, patients with left-sided CRC seem to benefit more from anti-EGFR therapy than patients with right-sided CRC. Further clinical trials, stratified for tumor location, are warranted.Entities:
Keywords: Anti-EGFR therapy; Anti-VEGF therapy; Biomarkers; Predictive value; Primary tumor location
Mesh：
Substances：
Year: 2017 PMID： 29279095 DOI： 10.1016/j.critrevonc.2017.11.003
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN： 1040-8428 Impact factor: 6.312